Recent data have also shown that [F-18]-AV-1451 binding in legacy postmortem material closely correlates with NFT Braak staging and regional tau burden [34], suggesting that [F-18]-AV-1451 holds promise as a biomarker for the in vivo staging and quantification of tau pathology in AD. Here, MAPT is linked to Alzheimer disease.